Funding for this research was provided by:
Johnson and Johnson
Received: 2 November 2022
Accepted: 15 December 2022
First Online: 26 December 2022
: The analyses using the IBM® MarketScan® Commercial and Medicare Supplemental databases were exempt from IRB approval by the New England Institutional Review Board (IRB) as this research project involved no risk to the subjects and the de-identified patient-level dataset was obtained through a license agreement with the data holder. Only deidentified data were used, and informed consent was not applicable.
: All authors are employees of Johnson & Johnson (JnJ) or DePuy Synthes (a JnJ Company) and receive salary and/or own stock in JnJ.